TY - JOUR
T1 - Aspen
T2 - The European Commission’s First Decision on Excessive Pricing in the Pharmaceuticals Sector
AU - Tyagi, Kalpana
N1 - Publisher Copyright:
© 2022, Lexxion Verlagsgesellschaft mbH. All rights reserved.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission’s case and Aspen’s well-planned strategy to systematically and uniformly increase prices across the Member States.
AB - On 10 February 2021, the Commission entered into a settlement decision with Aspen under Article 9 of Regulation 1/2003. The Commission investigated 'excessive pricing' by the South Africa-headquartered Aspen in six off-patent cancer drugs in the European Economic Area (EEA). These drugs had been off-patent for well over 50 years, and there seemed no rational prima facie justification for their unfairly high prices. This case note offers a critical discussion on the Commission’s case and Aspen’s well-planned strategy to systematically and uniformly increase prices across the Member States.
UR - http://www.scopus.com/inward/record.url?scp=85135032605&partnerID=8YFLogxK
U2 - 10.21552/core/2022/2/13
DO - 10.21552/core/2022/2/13
M3 - Article
SN - 2510-3148
VL - 6
SP - 173
EP - 179
JO - European Competition and Regulatory Law Review
JF - European Competition and Regulatory Law Review
IS - 2
ER -